AUTHORS
Fengxing Gu, Ruili Lv2, Jiansu Zhang3, Jiangfeng Yuan4, Xiaofei Zhou5, Hannah Horton6
AFFILIATIONS
1 Biocytogen Pharmaceuticals (Beijing), Beijing, China
2 Biocytogen Pharmaceuticals (Beijing), Beijing, China
3 Biocytogen Pharmaceuticals (Beijing), Beijing, China
4 Biocytogen Pharmaceuticals (Beijing), Beijing, China
5 Biocytogen Pharmaceuticals (Beijing), Beijing, China
6 Biocytogen, Waltham, United States
ABSTRACT
Introduction: Sickle cell anemia is an inherited hemoglobinopathy driven by a pathogenic variant in the human β-globin gene (HBB<sup>S</sup>). Mutant hemoglobin S undergoes polymerization under deoxygenated conditions, triggering red blood cell sickling, chronic hemolysis, vaso-occlusion, and progressive multi-organ injury. Current investigational therapeutics, including oligonucleotides, gene modifiers, and small molecules, require physiologically relevant animal models carrying human globin loci to recapitulate disease pathology and support efficacy testing.
Methods: The mouse Hba-a1/Hba-a2 genes were replaced with human HBA1/HBA2 to generate B-hHBA1/hHBA2 mice (129S2). The mouse Hbb-bs/Hbb-bt genes were replaced with human HBG1/HBG2/HBD/HBBs to generate B-hHBG1/hHBG2/hHBD/hHBBs mice. B-hHBA1/hHBA2/hHBG1/hHBG2/hHBD/hHBBs mice (B6; 129S) were produced by intercrossing the two single humanized strains. Hematology panel testing, serum biochemistry, and peripheral blood smear analysis were performed to characterize the model.
Results: The complete blood count test results reveal that, in comparison to wild-type control mice, there is a substantial decline in RBC, HGB, HCT, and PLT in sickle cell anemia mice. Conversely, these mice exhibit a significant increase in WBC, RDW, NRBC#, NRBC%, RET#, and RET%. Biochemistry analysis shows a substantial increase in ALT, AST, and TBIL in sickle cell anemia mice. The blood smear analysis results showed that sickle cell anemia mice exhibited a distinct and stable sickle red blood cell phenotype.
Conclusions: This compound humanized mouse strain carries the full set of human α-globin, fetal globin, δ-globin, and sickle mutant β-globin genes and recapitulates core hematologic, biochemical, and cellular hallmarks of human sickle cell anemia. This model represents a powerful in vivo platform for preclinical efficacy and safety evaluation of novel therapies targeting sickle cell disease.
DISCLOSURES
Hannah Horton: No relevant conflicts of interest to declare.